Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial.
Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ.
Scott AM, et al. Among authors: davis id.
J Clin Oncol. 2001 Oct 1;19(19):3976-87. doi: 10.1200/JCO.2001.19.19.3976.
J Clin Oncol. 2001.
PMID: 11579119
Clinical Trial.